Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aligos Therapeutics (ALGS) Revenue (2021 - 2025)

Aligos Therapeutics' Revenue history spans 5 years, with the latest figure at $169000.0 for Q4 2025.

  • For Q4 2025, Revenue fell 94.88% year-over-year to $169000.0; the TTM value through Dec 2025 reached $2.2 million, down 65.33%, while the annual FY2025 figure was $2.2 million, 39.46% down from the prior year.
  • Revenue reached $169000.0 in Q4 2025 per ALGS's latest filing, down from $741000.0 in the prior quarter.
  • In the past five years, Revenue ranged from a high of $13.9 million in Q4 2022 to a low of $140000.0 in Q1 2023.
  • Average Revenue over 5 years is $2.1 million, with a median of $1.2 million recorded in 2024.
  • Peak YoY movement for Revenue: surged 3689.37% in 2022, then tumbled 94.88% in 2025.
  • A 5-year view of Revenue shows it stood at $367000.0 in 2021, then soared by 3689.37% to $13.9 million in 2022, then plummeted by 85.55% to $2.0 million in 2023, then soared by 64.26% to $3.3 million in 2024, then crashed by 94.88% to $169000.0 in 2025.
  • Per Business Quant, the three most recent readings for ALGS's Revenue are $169000.0 (Q4 2025), $741000.0 (Q3 2025), and $965000.0 (Q2 2025).